Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06596668 · ClinicalTrials.gov registry record · Phase 1
Drug-Drug Interaction Study of Bomedemstat and Carbamazepine in Healthy Adult Participants (MK-3543-020)
A Phase 1 study, sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT06596668 is a Phase 1 study that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 16 participants.
The verdict
NCT06596668, a Phase 1 study, has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
Researchers have designed a study medicine called bomedemstat (MK-3543) as a new way to treat certain rare blood diseases. The purpose of this study is to learn what happens to bomedemstat in a person's body over time (a pharmacokinetic or PK study). Researchers will compare what happens to bomedemstat in the body when it is given alone and after multiple doses of another medicine called carbamazepine (CBZ).
Interventions
- DRUG carbamazepine
- DRUG bomedemstat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2024-10-02 |
| Est. Completion | 2025-03-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06596668
The ClinicalTrials.gov registry entry for NCT06596668 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which carbamazepine is the first listed.
NCT06596668 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06596668 about?
NCT06596668 is a clinical study titled "Drug-Drug Interaction Study of Bomedemstat and Carbamazepine in Healthy Adult Participants (MK-3543-020)". Researchers have designed a study medicine called bomedemstat (MK-3543) as a new way to treat certain rare blood diseases. The purpose of this study is to learn what happens to bomedemstat in a person's body over time (a pharmacokinetic or PK study). Researchers will compare what happens to bomedem...
What is the current status of trial NCT06596668?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2024-10-02. Estimated completion is 2025-03-11.
What interventions are being tested in trial NCT06596668?
The interventions under investigation include: carbamazepine (DRUG), bomedemstat (DRUG).
Who is sponsoring clinical trial NCT06596668?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.